Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 5/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 3/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.36 |
| ▸ | BRD2 | P25440 | 1/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.36 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710311 | 0.83 | FTO (0.41) | BRD4FTOCREBBPLCKFYN | |
| SCHEMBL6713399 | 0.83 | BRD4 (0.37) | BRD4CREBBPLCKFYNBRD2 | |
| SCHEMBL7071019 | 0.82 | ALDH1A1 (0.44) | ALBLMNATP53MAPT | |
| SCHEMBL6833879 | 0.81 | LMNA (0.43) | ALBLCKPRSS12LMNATP53 | |
| SCHEMBL6833857 | 0.80 | FTO (0.41) | BRD4FTOHCAR2ALBP2RY14 | |
| SCHEMBL6835707 | 0.78 | ALB (0.41) | ALBLMNATP53MAPT | |
| SCHEMBL6818878 | 0.78 | ALB (0.56) | ALBLCKLMNATP53MAPT | |
| SCHEMBL6835702 | 0.77 | MAPT (0.47) | ALBLMNATP53MAPT | |
| SCHEMBL6818253 | 0.77 | ROCK2 (0.42) | ALBLMNATP53MAPT | |
| SCHEMBL6833214 | 0.77 | KCNH2 (0.47) | BRD4FTOHCAR2ALBP2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | BRD4 1157/4885FTO 918/4885HCAR2 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.